NCT00645255终止3 期
A Multicenter, Double-Blind, Placebo-Controlled, Parallel Group Study to Examine the Longer-Term Efficacy and Safety of Meridia (Sibutramine Hydrochloride) in Obese Subjects
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 终止
- 发起方
- Abbott
- 入组人数
- 466
- 主要终点
- Body Weight Loss
研究概览
简要总结
The study was designed to evaluate the long term efficacy and safety of Meridia 15 mg daily in obese subjects.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •The subject must be able to communicate meaningfully with the investigator, be legally competent, provide written informed consent, and follow a specified diet and exercise program.
- •Female subjects must be nonlactating and must either be a) at least one year postmenopausal; or b) surgically sterilized by bilateral tubal ligation, bilateral oophorectomy or hysterectomy; or c) using adequate contraceptive precautions (i.e., oral contraceptives, approved hormonal implant, intrauterine device, diaphragm with spermicide, condom with spermicide).
- •A serum pregnancy test, which must be negative, is required of all females except those who are surgically sterile or postmenopausal.
- •The subject must be at least 18 years old.
- •The subject must have a systolic blood pressure <=140 mmHg, a diastolic blood pressure<=90 mmHg, and a pulse rate <=95 beats per minute (see Section VI.I.). Treated hypertensives are allowed in the study.
- •The subject must have been enrolled in a nonpharmacologic weight loss program with documented weight loss of >=10 kg maintained for at least 6 months, have gained back <50% of their peak lost weight (while currently maintaining a weight loss of >=10 kg), and be stabilized on a weight-maintaining diet for at least 1 month prior to screening.
- •The subject's body mass index (BMI) must be >=27 kg/m2 and <=40 kg/mg2, rounded to the nearest whole unit, and must have been >=30 kg/m2 prior to initiation of the nonpharmacological weight loss program prior to screening.
- •The subject must have lived in the immediate geographic area for at least 2 years prior to screening.
- •If the subject is on chronic medication, the dose must have been constant for at least two months prior to screening.
排除标准
- •The subject must not have a history of anorexia nervosa.
- •The subject must not have a history of clinically significant cardiac disease, any clinically significant abnormal cardiac condition, or be known to have a clinically significantly abnormal ECG. Specifically excluded conditions include coronary artery disease, clinically significant cardiac arrhythmias, and congestive heart failure.
- •The subject must not have a history of stroke.
- •The subject must not have a history of narrow angle glaucoma.
- •The subject must not have an organic cause of obesity (e.g., untreated hypothyroidism).
- •The subject must not have a history of seizures.
- •The subject must not have severe renal or hepatic dysfunction.
- •The subject must not be using any of the following medications while taking study medication: monoamine oxidase inhibitors (e.g., furazolidone, phenelzine, procarbazine HCl, selegiline), lithium, serotonin reuptake inhibitors, opioids (e.g., dextromethorphan, meperidine, pentazocine, fentanyl), prescribed or over-the-counter weight loss agents, centrally acting appetite suppressants, tryptophan, migraine agents (e.g., sumatriptan succinate, dihydroergotamine) or any other medication that, in the opinion of the Investigator, may pose harm to the subject, obscure the effects of study medication or interfere with the process of drug absorption, distribution, metabolism, or excretion (i.e., enzyme inducers or enzyme inhibitors). The regular use of sympathomimetics (e.g. cough and cold remedies, asthma medication) is contraindicated during the study. Study medication should be discontinued for 3 days before the use of opioids. THE SUBJECT SHOULD NOT BE TAKEN OFF ANTIDEPRESSANTS IN ORDER TO BE PLACED IN THE STUDY.
- •The subject must not have a history of hypersensitivity to MERIDIA.
- •The subject must not have a history of alcohol or drug addiction.
研究组 & 干预措施
1
Other
Single-blind Placebo Run-in with behavioral intervention called Health Management Resources Maintenance Program which provided weekly classes for 12 months with meal replacement
干预措施: placebo (Drug)
2
Placebo Comparator
Double-blind Treatment with behavioral intervention called Health Management Resources Maintenance Program which provided weekly classes for 12 months with meal replacement
干预措施: sibutramine or placebo (Drug)
结局指标
主要结局
Body Weight Loss
时间窗: Mean Change From Baseline
次要结局
- Body Mass Index (BMI)(Mean Change From Baseline)
- Waist/Hip Circumference(Mean Change From Baseline)
研究者
相似试验
已完成
3 期
Clinical Trial of Safety and Efficacy of New Dosage Schedule for Dietressa Drug in Treatment of Obese PatientsObesityNCT01570829Materia Medica Holding331
终止
3 期
A Two Year Safety and Efficacy Study in Obese Patients (0364-015)(TERMINATED)ObesityNCT00131404Merck Sharp & Dohme LLC2,400
已完成
2 期
A Study of the Safety of R256918 in Obese PatientsNutritional and Metabolic DiseasesMetabolic DiseasesNutrition DisordersOverweightObesityNCT01041677Johnson & Johnson Pharmaceutical Research & Development, L.L.C.71
终止
3 期
A Study of MK0364 in Obese Patients (0364-014)ObesityNCT00131391Merck Sharp & Dohme LLC2,400
已完成
2 期
Study to Evaluate ARD-101 in Adults With ObesityObesityNCT05121441Aardvark Therapeutics, Inc.20